Another take on CMV

ViroPharma Inc. believes that its maribavir cytomegalovirus UL97 kinase inhibitor doesn't cause immunosuppression, which could make the small molecule the first prophylactic treatment to guard against CMV in bone marrow transplant patients.

VPHM started a double-blind, placebo-controlled Phase II trial in the indication last week. Although safety is the primary endpoint, secondary endpoints include prevention of CMV reactivation (see B13). ...